Bayer and AskBio reveal early safety data for Parkinson's gene therapy, plot PhII study
04 Jan 2024
Gene TherapyPhase 1Phase 2
Bayer and its subsidiary AskBio touted early data from a small, early trial evaluating the safety of its gene therapy for Parkinson’s disease and announced plans for a Phase II study Thursday morning.
The Phase Ib trial hit its primary endpoint, which was to show the safety of a one-time delivery of the gene therapy, dubbed AB-1005, into 11 patients split between two cohorts. Six patients had mild stage Parkinson’s, while five had moderate stage.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.